You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
Kedrion Biosc - Front Image

news

BACK

  1. 27-06-2017

    Cash Tender Offer for Notes due 24 April 2019

    Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019

    read more 

  2. 31-03-2017

    Annual Results 2016

    Consolidated turnover of 659.3 million Euro, a growth of 89 million Euro or 15.6%

    read more 

  3. 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has decided to accept for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 

  4. 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019.

    read more 

  5. 12-11-2014

    Kedrion joins the programme “ELITE for Large Corporates”

    Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

    read more 

  6. 15-10-2014

    New generation immunoglobulins: in January production of clinical batches

    The first batch for the feasibility test was produced at the Gödöllő plant in September with results in compliance with specifications

    read more 

  7. 08-09-2014

    Kedrion’s key financials and milestones in the new Investor Relations area

    Website area dedicated to providing the financial community with latest information regarding the Kedrion Bond

    read more 

  8. 09-09-2014

    Bond marked by Wide Distribution

    The success of the operation is reflected in the wide variety of investors involved

    read more 

  9. 09-09-2014

    Issuance of Kedrion Bond a success

    The issuance took place after a three-day European road-show in London, Paris and Milan

    read more 

Pages

For more information please contact: investor@kedrion.com